FDA Office of Hematology Oncology Products, Now Called Office of Oncologic Diseases
FDA Approves Biosimilar Ziextenzo (pegfilgrastim-bmez)
CMS Issues RFI on Oncology Care First Model
CMS Releases CY 2020 Final Medicare Payment Rules
FDA Approves Niraparib for HRD-positive Advanced Ovarian Cancer
Cosponsors for H.R. 3502 Surprise Billing Legislation Reach 102
Blood Cancer Patients Covered by Medicare Often Delay or Skip Treatment, Study Finds
NAM Issues Report on Systems Approach to Supporting Clinician Well-Being
CMMI Plans Public Listening Session on Potential Future Oncology Payment Model
ACCC Joins in Letter Urging CMS to Protect Timely to Advanced Diagnostics
Three Scientists Receive Nobel Prize in Medicine for Work on Cells and Oxygen
ACCC Comments to CMS on Proposed 2020 OPPS & PFS Rules
FDA Approves Daratumumab in Combination for Frontline Multiple Myeloma
FDA Approves Non-Invasive CRC Screening Test for Eligible Individuals Ages 45 to 49
ACCC Comments to CMS on Proposed RO Model
Pelosi Unveils Price Negotiation Bill, Similar to Draft Plan
FDA Approves Apalutamide for Metastatic Castration-Sensitive Prostate Cancers
FDA Consumer Information on Respiratory Illnesses Associated with Vaping Products
CMS Announces Support for Florida in Preparation for Hurricane Dorian
USPSTF Updates Recommendation on Screening, Counseling, Testing for BRCA-related Cancer
FDA Approves Fedratinib for Intermediate-2 or High-Risk Myelofibrosis
FDA Approves Entrectinib for ROS1-Positive, Metastatic NSCLC
CMS Finalizes NCD for CAR T-Cell Therapy
New NCCN Guidelines Address Small Intestine Cancers
HHS Issues Plan Outlining 2 Paths for Prescription Drug Importation
FDA Approves Pembrolizumab for PD-L1 Positive Advanced SCC of Esophagus
FDA Approves Darolutamide for Non-metastatic Castration-resistant Prostate Cancer
CMS Releases Proposed 2020 OPPS and PFS Rules
FDA Requests Recall of Certain Textured Breast Implants
Senate Finance Committee Reveals Drug-Pricing Legislation
